Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUD-RELAX1-070 venetoclax + cytarabine + mitoxantrone in relapsed/refractory AML
2024-514018-12-00Phase 2Completed
- Sponsor
- Technische Universität Dresden
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), sponsored by Technische Universität Dresden. Primary endpoints: Maximum tolerated dose of cytarabine in combination with venetoclax plus mitoxantrone (Phase I escalation part) and Complete remission (CR) and complete remission with incomplete hematologic recovery (CRi) rate (Phase II expansion part). Started Apr 2020; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-514018-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514018-12-00.